



# Antimicrobial Stewardship in Australian Health Care

2018

Published by the Australian Commission on Safety and Quality in Health Care

Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600

Email: [mail@safetyandquality.gov.au](mailto:mail@safetyandquality.gov.au)

Website: [www.safetyandquality.gov.au](http://www.safetyandquality.gov.au)

ISBN: 978-1-925665-40-6

© Australian Commission on Safety and Quality in Health Care 2018

All material and work produced by the Australian Commission on Safety and Quality in Health Care (the Commission) is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Commission has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties and where otherwise noted, all material presented in this publication is licensed under a Creative Commons Attribution–NonCommercial–NoDerivatives 4.0 International licence.

Enquiries about the licence and any use of this publication are welcome and can be sent to [communications@safetyandquality.gov.au](mailto:communications@safetyandquality.gov.au).

The Commission's preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. Antimicrobial Stewardship in Australian Health Care 2018. Sydney: ACSQHC; 2018

Disclaimer

The content of this document is published in good faith by the Commission for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your healthcare provider for information or advice on particular healthcare choices.

This document includes the views or recommendations of its authors and third parties. Publication of this document by the Commission does not necessarily reflect the views of the Commission, or indicate a commitment to a particular course of action. The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

# Acknowledgements

Antimicrobial Stewardship in Australian Health Care 2018 has been developed through the contributions of many individuals and organisations who are committed to improving antimicrobial use in hospitals and reducing the risk of harm to patients from inappropriate antimicrobial prescribing. The Australian Commission on Safety and Quality in Health Care wishes to thank the following contributing authors for their expertise and time given to the writing of this publication:

- Dr Tara Anderson – Infectious Diseases Physician and Clinical Microbiologist, Medical Advisor Infection Prevention and Control, Royal Hobart Hospital, and Specialist Medical Advisor Tasmanian Infection Prevention and Control Unit (particularly Chapter 2)
- Dr Noleen Bennett – National Centre for Antimicrobial Stewardship (particularly Chapter 12)
- Dr Penelope Bryant - Paediatric Infectious Diseases Physician and General Paediatrician, the Royal Children's Hospital (particularly Chapter 14)
- Associate Professor Kirsty Busing – National Centre for Antimicrobial Stewardship (particularly Chapters 3 and 6)
- Clinical Associate Professor Susan Benson PathWest Laboratory Medicine, Western Australian Department of Health and University of Western Australia (particularly Chapter 9)
- Dr Celia Cooper – SA Pathology, SA Health (particularly Chapters 5, 8 and 14)
- Dr Jonathan Dartnell – NPS MedicineWise (particularly Chapters 7, 10 and 13)
- Ms Margaret Duguid – Australian Commission on Safety and Quality in Health Care (contribution to all Chapters)
- Conjoint Associate Professor John Ferguson Hunter New England Local Health District (particularly Chapter 9)
- Ms Fiona Gotterson – Australian Commission on Safety and Quality in Health Care (particularly Chapters 3, 5 and 12)
- Dr David Kong – Ballarat Health Services and Centre for Medicine Use and Safety, Monash University (particularly Chapter 11)
- Associate Professor David Looke – Infectious Diseases Physician and Clinical Microbiologist, Princess Alexandra Hospital; and Associate

Professor, University of Queensland (particularly Chapter 6)

- Professor Graeme Nimmo – Pathology Queensland, Queensland Health (particularly Chapter 9)
- Ms Lisa Pulver – NPS MedicineWise (particularly Chapters 7, 10 and 13)
- Professor Debra Rowett – NPS MedicineWise (particularly Chapters 7, 10 and 13)
- Professor Karin Thursky – National Centre for Antimicrobial Stewardship (particularly Chapter 4)
- Professor John Turnidge AO – Australian Commission on Safety and Quality in Health Care (particularly Chapters 1 and 3)
- Dr Helen Van Gessel – Albany Hospital (particularly Chapter 2)
- Dr Morgyn Warner – SA Pathology, SA Health (particularly Chapter 1)
- Dr Jeanie Yoo – NPS MedicineWise (particularly Chapters 10 and 13).

The Commission also wishes to extend its thanks to the following individuals who have provided their considered advice in the review of the content of this book:

- Dr Sean Beggs, Paediatrician, The Royal Hobart Hospital (particularly Chapter 14)
- Dr Philippa Binns – public health physician and general practitioner
- Ms Amy Chen, AMS Pharmacist, Monash Children's Hospital (particularly Chapter 14)
- Dr Stuart Crisp, Paediatrician, Orange, NSW (particularly Chapter 14)
- Professor Chris Del Mar – Centre for Research in Evidence-Based Practice, Bond University
- Dr Kylie Easton – NPS MedicineWise
- Ms Zoy Goff, AMS Pharmacist, Perth Children's Hospital (particularly Chapter 14)
- Associate Professor Thomas Gottlieb - Senior Staff Specialist, Microbiology & Infectious Diseases, Concord Hospital
- Ms Nicolette Graham, AMS Pharmacist, Queensland Children's Hospital (particularly Chapter 14)
- Dr Malene Hansen – Centre for Research in Evidence-Based Practice, Bond University
- Ms Dorothy Harrison – consumer representative reviewer

- Ms Aine Heaney – NPS MedicineWise
- Dr Adam Irwin, conjoint Senior Lecturer and academic lead for Paediatric Infectious Disease at Children’s Health Queensland and the University of Queensland (particularly Chapter 14)
- Mr Tony Lai, AMS Pharmacist, The Children’s Hospital at Westmead (particularly Chapter 14)
- Ms Elaine Lum – Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology
- Dr Carolyn Leerdam, Paediatrician, Canberra Hospital (particularly Chapter 14)
- Professor Jennifer May, Member, ACSQHC Primary Care Committee (particularly Chapter 13)
- Dr Amanda McCullough – Centre for Research in Evidence-Based Practice, Bond University
- Dr Brendan McMullan, Paediatric ID Specialist, Sydney Children’s Hospital, Randwick (particularly Chapter 14)
- Dr Geoffrey Playford - Director, Infection Management Services, Princess Alexandra Hospital
- Ms Amber Polles, KP Health (particularly Chapter 13 and 14)
- Dr Deena Parbhoo, AMS Paediatrician, Monash Children’s Hospital (particularly Chapter 14)
- Associate Professor Owen Robinson -Infectious Diseases Physician, Royal Perth Hospital
- Dr Kelly Shaw, KP Health (particularly Chapter 13 and 14)
- Ms Vanessa Simpson – NPS MedicineWise
- Dr Andrew Staib - Emergency Medicine, Princess Alexandra Hospital
- Dr Clair Sullivan - Consultant Endocrinologist and Medical Informatician, Princess Alexandra Hospital
- Dr Helena Williams, Chair, ACSQHC Primary Care Committee (particularly Chapter 13).

A number of Commission staff were also involved in the writing and review of this publication, and the Commission wishes to acknowledge:

- Ms Debbie Carter
- Professor Marilyn Cruickshank
- Ms Fiona Doukas
- Dr Nicola Dunbar
- Dr Robert Herkes
- Ms Eliza McEwin
- Adjunct Professor Kathy Meleady PSM
- Adjunct Professor Debora Picone AO
- Ms Naomi Poole
- Ms Kim Stewart
- Ms Lucia Tapsall
- Mr Michael Wallace
- Ms Kristin Xenos

In addition, the Commission wishes to acknowledge the members of the Society of Hospital Pharmacists of Australia Infectious Diseases Committee of Specialty Practice for their contribution in reviewing this publication; and the staff of Biotext for their expert review, editing and design services.

# Contents

Summary.....	1
Key issues .....	3
The challenge .....	3
The response.....	3
Australian framework for AMS .....	3
Essential elements of antimicrobial stewardship .....	3
This publication .....	4
Aim.....	4
Structure .....	4
Chapter 1: Evidence for antimicrobial stewardship.....	7
Acronyms and abbreviations .....	10
1.1 Introduction.....	11
1.2 Challenge and impact of antimicrobial resistance.....	12
1.2.1 Association between antimicrobial use and resistance .....	12
1.2.2 Consequences of antimicrobial resistance .....	13
1.3 Australian framework for antimicrobial stewardship .....	14
1.3.1 National standards and guidelines .....	14
1.3.2 National Antimicrobial Resistance Strategy .....	17
1.3.3 Antimicrobial stewardship in the states and territories .....	17
1.3.4 Therapeutic Guidelines .....	17
1.3.5 Surveillance of antimicrobial use and resistance in Australia .....	18
1.3.6 Education and awareness raising .....	19
1.3.7 Antimicrobial stewardship research .....	20
1.3.8 Professional societies and organisations .....	20
1.4 Antimicrobial use .....	21
1.4.1 Factors contributing to unnecessary and inappropriate antimicrobial use .....	21
1.4.2 Antimicrobial use in Australia .....	21
1.4.3 Harmful effects of antimicrobial use .....	21
1.5 Antimicrobial stewardship .....	22
1.5.1 Effective antimicrobial stewardship .....	22
1.5.2 Evidence to support the benefits of antimicrobial stewardship .....	24
1.5.3 Unintended consequences of antimicrobial stewardship programs .....	27
References .....	29
Appendix A: Examples of antimicrobial stewardship (AMS) activities and resources in Australian states and territories .....	34

Chapter 2: Establishing and sustaining an antimicrobial stewardship program.....	35
Acronyms and abbreviations .....	38
2.1 Introduction .....	39
2.2 Essential elements of antimicrobial stewardship programs .....	40
2.3 Structure and governance .....	41
2.3.1 Safety and quality improvement .....	41
2.3.2 Governance .....	41
2.3.3 Executive leadership .....	44
2.3.4 Clinical leadership .....	44
2.4 Antimicrobial stewardship committee and team .....	45
2.4.1 Antimicrobial stewardship committee .....	45
2.4.2 Antimicrobial stewardship team .....	48
2.5 Antimicrobial stewardship program plan .....	49
2.5.1 Assessing readiness to implement an antimicrobial stewardship program or intervention.....	49
2.5.2 Reviewing existing policies and prescribing guidelines.....	53
2.5.3 Reviewing local data on antimicrobial use and resistance .....	55
2.5.4 Determining priority areas for antimicrobial stewardship activities .....	56
2.5.5 Identifying effective interventions .....	57
2.5.6 Defining measurable goals and outcomes .....	58
2.5.7 Documenting and implementing the antimicrobial stewardship plan .....	59
2.5.8 Educating the workforce .....	59
2.5.9 Developing and implementing a communication plan .....	60
2.6 Sustaining the antimicrobial stewardship program .....	60
Resources .....	61
References .....	63
Appendix A: Examples of successful and sustained antimicrobial stewardship programs.....	66
Chapter 3: Strategies and tools for antimicrobial stewardship .....	75
Acronyms and abbreviations .....	78
3.1 Introduction .....	79
3.2 Prescribing guidelines .....	81
3.2.1 National guidelines .....	81
3.2.2 Local guidelines .....	81
3.2.3 Promoting guideline uptake .....	82
3.2.4 Tools and resources to support guideline implementation .....	82
3.2.5 Education and feedback .....	83
3.2.6 Antimicrobial stewardship care bundles .....	83
3.3 Formularies and approval systems .....	83
3.3.1 National formulary .....	83
3.3.2 State and territory formularies .....	84
3.3.3 Hospital formularies .....	84
3.3.4 Antimicrobial approval systems .....	85

<b>3.4 Post-prescription reviews</b> .....	<b>87</b>
3.4.1 Who should perform reviews in hospitals? .....	87
3.4.2 Which patients should be reviewed? .....	89
3.4.3 What should be included in the feedback? .....	89
3.4.4 How should feedback be provided? .....	89
3.4.5 Prescription review at transitions of care .....	90
3.4.6 Post-prescription reviews in the community setting .....	90
<b>3.5 Point-of-care interventions</b> .....	<b>91</b>
3.5.1 Directing therapy based on results from microscopy and other rapid tests .....	91
3.5.2 Directing therapy based on culture and susceptibility test results .....	91
3.5.3 Optimising dosing .....	91
3.5.4 Limiting toxicity .....	92
3.5.6 Changing the duration of therapy .....	92
3.5.7 Switching from intravenous to oral delivery .....	92
3.5.8 Escalating to formal expert clinical review .....	93
<b>Resources</b> .....	<b>94</b>
<b>References</b> .....	<b>95</b>
<b>Chapter 4: Information technology to support antimicrobial stewardship</b> .....	<b>99</b>
<b>Acronyms and abbreviations</b> .....	<b>102</b>
<b>4.1 Introduction</b> .....	<b>103</b>
<b>4.2 Electronic clinical decision support systems</b> .....	<b>104</b>
4.2.1 Passive decision support systems and smartphone apps .....	105
4.2.2 Electronic approval systems .....	108
4.2.3 Electronic surveillance and infection prevention systems .....	109
4.2.4 Electronic prescribing and medication management systems .....	110
4.2.5 Advanced decision support systems .....	111
4.2.6 Implementing electronic clinical decision support systems for antimicrobial stewardship .....	112
4.2.7 Electronic clinical decision support in primary care .....	113
<b>4.3 Data collection and reporting</b> .....	<b>114</b>
<b>4.4 Telehealth</b> .....	<b>115</b>
<b>Resources</b> .....	<b>117</b>
<b>References</b> .....	<b>118</b>
<b>Chapter 5: Antimicrobial stewardship education for clinicians</b> .....	<b>123</b>
<b>Acronyms and abbreviations</b> .....	<b>126</b>
<b>5.1 Introduction</b> .....	<b>127</b>
<b>5.2 Key elements of antimicrobial stewardship education</b> .....	<b>128</b>
5.2.1 Audiences .....	128
5.2.2 Principles of education on antimicrobial stewardship .....	129
5.2.3 Antimicrobial stewardship competencies and standards .....	129
5.2.4 Influence of the pharmaceutical industry .....	131
5.2.5 Evaluation of educational activities .....	132

5.3 Antimicrobial stewardship education for different groups and stages .....	132
5.3.1 Undergraduate training .....	132
5.3.2 Early-career development .....	133
5.3.3 Continuing education and professional development .....	134
5.3.4 Education and training for antimicrobial stewardship teams .....	136
5.3.5 Specialist training .....	137
5.4 Education resources .....	137
5.4.1 Guidelines .....	137
5.4.2 Websites and online learning resources .....	137
5.4.3 Educators .....	138
Resources .....	139
References .....	140
Appendix A: Managing conflicts of interest and relationships with the pharmaceutical industry – further reading and links .....	143
Appendix B: Example of a ‘Did you know’ email for clinicians .....	144
Chapter 6: Measuring performance and evaluating antimicrobial stewardship programs .....	147
Acronyms and abbreviations .....	150
6.1 Introduction .....	151
6.2 Key elements of antimicrobial stewardship measurement .....	152
6.2.1 What should be measured? .....	152
6.2.2 Measurement approaches .....	152
6.3 Structure measures .....	152
6.3.1 Hospitals .....	152
6.3.2 Community .....	154
6.4 Process measures .....	154
6.5 Outcome measures .....	155
6.5.1 Improved patient outcomes .....	156
6.5.2 Improved patient safety .....	156
6.5.3 Reduced resistance .....	156
6.5.4 Reduced costs .....	157
6.5.5 Qualitative and other related measures of program activity .....	157
6.6 Balancing measures .....	157
6.7 Surveillance of antimicrobial use .....	158
6.7.1 Measuring the volume of antimicrobial use in hospitals .....	158
6.7.2 Measuring the volume of antimicrobial use in the community .....	160
6.7.3 Reporting and monitoring use data at the local level .....	161
6.8 Auditing the quality of antimicrobial prescribing .....	164
6.8.1 Auditing prescribing in hospitals .....	164
6.8.2 Auditing prescribing in the community .....	166
6.8.3 Quality improvement audits .....	167



6.9 Reporting, feedback and use of data .....	168
6.9.1 Health service organisation reports .....	168
6.9.2 State and territory reports .....	168
6.9.3 National reports .....	168
6.9.4 Use of data for benchmarking .....	169
Resources .....	171
References .....	172
Chapter 7: Involving consumers in antimicrobial stewardship .....	177
Acronyms and abbreviations .....	180
7.1 Introduction .....	181
7.2 Consumer awareness and expectations .....	182
7.2.1 Consumer understanding of when antimicrobials are needed .....	182
7.2.2 Consumer awareness and understanding of antimicrobial resistance .....	182
7.2.3 Previous experience of antimicrobials .....	183
7.3 Key messages and communication .....	183
7.3.1 Reassurance .....	183
7.3.2 Health literacy .....	183
7.3.3 Communication with consumers in different settings and circumstances .....	185
7.4 Consumer resources and tools .....	186
7.4.1 Before the consultation .....	186
7.4.2 During the consultation .....	187
7.4.3 After the consultation .....	188
7.4.4 Reaching and engaging consumers nationally .....	188
7.4.5 Antibiotic Awareness Week .....	190
Resources .....	191
References .....	192
Chapter 8: Role of the infectious diseases service in antimicrobial stewardship.....	195
Acronyms and abbreviations .....	198
8.1 Introduction .....	199
8.2 Leadership .....	199
8.2.1 Participating in the antimicrobial stewardship team and committees .....	200
8.2.2 Implementing and maintaining antimicrobial policies and guidelines .....	201
8.3 Expert advice .....	201
8.3.1 Specific situations requiring infectious diseases physician expertise .....	202
8.3.2 Support for external organisations .....	203
8.4 Support for formularies and approval systems .....	204
8.4.1 Formularies .....	204
8.4.2 Approval systems .....	204
8.5 Prescription review with feedback .....	205
8.5.1 Antimicrobial stewardship team rounds .....	205
8.5.2 Conflicting advice .....	205

8.6 Monitoring antimicrobial use and evaluating interventions .....	206
8.7 Liaison .....	207
8.7.1 Liaison within hospitals .....	207
8.7.2 Interacting with the pharmaceutical industry .....	207
8.8 Role in education .....	208
Resources .....	209
References .....	209
<b>Chapter 9: Role of the clinical microbiology service in antimicrobial stewardship .....</b>	<b>213</b>
Acronyms and abbreviations .....	216
9.1 Introduction .....	217
9.2 Overview of the diagnostic testing process .....	217
9.3 Pre-analytical phase: microbiology process .....	218
9.3.1 Selecting diagnostic tests .....	218
9.3.2 Collecting and transporting samples .....	220
9.3.3 Commenting on specimen quality .....	221
9.4 Analytical phase: microbiological analytical practice .....	221
9.4.1 Rapid diagnostics and testing .....	221
9.4.2 Antimicrobial susceptibility testing .....	222
9.5 Post-analytical phase: microbiology reporting .....	222
9.5.1 Timeliness of test reporting and integration with antimicrobial stewardship programs .....	222
9.5.2 Reporting and interpreting results .....	222
9.5.3 Cascade reporting .....	224
9.5.4 Communicating critical results .....	225
9.6 Specific situations that need clinical microbiology service expertise .....	225
9.6.1 Support for high-risk units .....	225
9.6.2 Cumulative antibiogram analysis .....	226
9.6.3 Signal and critical antimicrobial resistances (CARs) .....	226
9.6.4 Therapeutic drug monitoring and review .....	228
9.6.5 Linking microbiology results with electronic prescribing .....	228
9.6.6 Measuring performance of the clinical microbiology service as part of the antimicrobial stewardship program .....	228
9.7 Role in education .....	229
Resources .....	230
References .....	231
<b>Chapter 10: Role of prescribers in antimicrobial stewardship .....</b>	<b>237</b>
Acronyms and abbreviations .....	240
10.1 Introduction .....	241
10.2 Prescriber concerns and influences .....	242
10.2.1 Prescriber perspectives on antimicrobial resistance .....	242
10.2.2 Policies and guidelines .....	242

10.2.3 Diagnostic uncertainty .....	243
10.2.4 Influence of others .....	243
10.2.5 Prescribers in aged care .....	244
10.2.6 Non-medical prescribers .....	244
<b>10.3 Prescriber strategies .....</b>	<b>245</b>
10.3.1 Antimicrobial stewardship prescribing principles .....	245
10.3.2 Prescribing in specific situations .....	246
<b>10.4 Prescriber resources and tools .....</b>	<b>247</b>
10.4.1 Guidelines and antimicrobial information .....	247
10.4.2 Antimicrobial Stewardship Clinical Care Standard .....	247
10.4.3 Education and professional development .....	247
<b>Resources .....</b>	<b>248</b>
<b>References .....</b>	<b>249</b>
<b>Chapter 11: Role of the pharmacist and pharmacy services in antimicrobial stewardship .....</b>	<b>253</b>
<b>Acronyms and abbreviations .....</b>	<b>256</b>
<b>11.1 Introduction .....</b>	<b>257</b>
<b>11.2 Pharmacists and antimicrobial stewardship .....</b>	<b>257</b>
11.2.1 Activities in different settings .....	258
11.2.2 Pharmacy managers .....	261
11.2.3 Roles of antimicrobial stewardship pharmacists .....	262
<b>11.3 Leadership .....</b>	<b>262</b>
11.3.1 Promoting uptake and compliance with national standards for antimicrobial stewardship .....	263
11.3.2 Developing and maintaining antimicrobial guidelines .....	263
<b>11.4 Expert advice .....</b>	<b>263</b>
11.4.1 Providing expert advice to clinicians, patients and carers .....	263
11.4.2 Participating in antimicrobial stewardship ward rounds .....	263
11.4.3 Initiating point-of-care interventions .....	264
<b>11.5 Formularies and approval systems .....</b>	<b>264</b>
<b>11.6 Monitoring antimicrobial use and evaluating interventions .....</b>	<b>264</b>
<b>11.7 Liaison .....</b>	<b>265</b>
<b>11.8 Education .....</b>	<b>265</b>
11.8.1 Antimicrobial stewardship education for pharmacists .....	265
11.8.2 Pharmacists' role in education .....	267
<b>Resources .....</b>	<b>268</b>
<b>References .....</b>	<b>269</b>
<b>Appendix A: Examples of training and educational opportunities for AMS pharmacists .....</b>	<b>271</b>

Chapter 12: Role of nurses, midwives and infection control practitioners in antimicrobial stewardship .....	273
Acronyms and abbreviations .....	276
12.1 Introduction .....	277
12.2 Nursing and midwifery practice and antimicrobial stewardship .....	277
12.3 Facilitating nursing and midwifery involvement .....	280
12.3.1 Planning for nursing and midwifery involvement .....	280
12.3.2 Promoting a safety culture .....	282
12.3.3 Education .....	283
12.3.4 Resources and tools .....	284
12.4 Advanced and specialist practice roles .....	285
12.4.1 Nurse practitioners .....	285
12.4.2 Infection control practitioners .....	286
Resources .....	289
References .....	290
 Chapter 13 – Role of general practice in antimicrobial stewardship.....	 293
Acronyms and abbreviations .....	296
13.1 Introduction .....	297
13.1.1 Antimicrobial resistance in the community .....	298
13.1.2 Antimicrobial use in the community .....	298
13.1.3 Antimicrobial use and general practice .....	299
13.2 Factors that influence antimicrobial prescribing in general practice .....	299
13.2.1 General practice characteristics .....	299
13.2.2 Patient characteristics .....	300
13.2.3 Indigenous populations .....	300
13.2.4 Residential aged care facilities .....	300
13.2.5 Patient expectations .....	300
13.2.6 Diagnostic uncertainty .....	301
13.3 Antimicrobial stewardship strategies for general practice .....	301
13.3.1 Before the consultation .....	302
13.3.2 During the consultation .....	303
13.3.2 After the consultation .....	304
13.4 Clinical governance and leadership for antimicrobial stewardship .....	307
13.4.1 Professional leadership .....	307
13.4.2 National leadership .....	307
13.4.3 Regional leadership .....	307
13.4.4 Practice leadership .....	307
Resources .....	308
References .....	309

Chapter 14 – Antimicrobial stewardship in the care of children.....	312
Contents .....	313
Acronyms and Abbreviations. ....	314
Key Points .....	315
14.1 Introduction.....	316
14.1.1 Antimicrobial use in children.....	316
14.1.2 Antimicrobial resistance and children.....	317
14.1.3 Antimicrobial stewardship in paediatric care.....	317
14.2 Factors that influence antimicrobial prescribing in children .....	318
14.2.1 Anatomical and physiological factors .....	318
14.2.2 Antimicrobial access and safety factors .....	318
14.2.3 Other factors .....	319
14.3 Antimicrobial Stewardship strategies for paediatric care .....	320
14.3.1 Reduce antimicrobial prescribing in primary care .....	320
14.3.2 Limit duration of antimicrobial therapy .....	321
14.3.3 Intravenous to oral switch .....	322
14.3.4 Antimicrobial dose optimisation .....	323
14.3.5 Rapid diagnostics .....	323
14.4 Implementing and leading antimicrobial stewardship in paediatric care .....	323
14.4.1 A team approach to AMS .....	323
14.4.2 Plans and strategies for AMS programs .....	324
14.4.3 Targeted approaches .....	325
14.4.4 Education .....	325
14.5 Measuring AMS performance .....	326
14.5.1 Rate of antimicrobial use .....	326
14.5.2 Appropriateness of use .....	326
14.5.3 Outcome measures .....	327
Resources .....	328
References .....	330
Glossary .....	G1-G11